| Luo, Yanlin |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer |
|
|
| Terminated | 1 | 56 | RoW | Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Ovarian Cancer | 05/23 | 05/23 | | |
| Hu, Jianbing |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
